Skip to Content

WPI 3635 (Levetiracetam extended release 500 mg)

Pill imprint WPI 3635 has been identified as Levetiracetam extended release 500 mg.

Levetiracetam is used in the treatment of seizures; epilepsy; new daily persistent headache; bipolar disorder; hyperekplexia (and more), and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy. Levetiracetam 500 mg is classified as a Schedule N controlled substance under the Controlled Substance Act (CSA).

Levetiracetam extended release 500 mg WPI 3635
Levetiracetam extended release
WPI 3635
500 mg
Prescription only
Drug Class:
Pyrrolidine anticonvulsants
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
N - Not a controlled drug
Watson Laboratories, Inc.

View Details Print Page Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2015, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.